In a study of new applicants for recent vision loss rehabilitative services, 7% had current major depression and 26.9% met the criteria for subthreshold depression.
Background: Many studies have established that a large percentage of patients with posttraumatic stress disorder (PTSD) have comorbid major depressive disorder. Other studies have found that patients with PTSD or a history of childhood trauma have an increased rate of psychotic symptoms. In the present report from the Rhode Island Methods to Improve Diagnosis and Services project, we examine whether an association exists between psychotic subtyping of major depressive disorder and PTSD.. Method: Five hundred psychiatric outpatients were interviewed with the Structured Clinical Interview for DSM-IV. Results: Almost half of the 500 patients had nonbipolar major depressive disorder (N = 235, 47.0%), 45 (19.1%) of whom had PTSD. Nineteen patients had psychotic depression, 216 had nonpsychotic depression. Compared with patients with nonpsychotic depression, the patients with psychotic depression were nearly 4 times more likely to have PTSD (57.9% vs. 15.7%, Fisher exact test, p = .0001). Conclusion: ...
Escitalopram has been approved by FDA in the treatment of adolescents with major depressive disorder since March 2009. Although Wagner and colleagues reported that escitalopram has a tendency toward positive findings for the treatment of pediatric patients with major depressive disorder in their study it was found that this effect has not reached a statistical significance. Noteworthy the authors reported statistical significance for escitalopram when they only included adolescent subgroup into further analysis. However, there are also clinical trials in the literature reporting the effectiveness of escitalopram on adolescence major depressive disorder (Emslie, Findling). It was indicated that no serious adverse effect of escitalopram was reported in these studies comparing escitalopram with placebo. In this study the authors aimed to investigate the effect and reliability of the drug in the treatment of adolescents with major depressive disorder and/or anxiety disorders. Additionally, cognitive ...
Title:Catechol-O-Methyltransferase (COMT) Pharmacogenetics in the Treatment Response Phenotypes of Major Depressive Disorder (MDD). VOLUME: 11 ISSUE: 3. Author(s):Neslihan Aygun Kocabas. Affiliation:Universite Libre de Bruxelles, Laboratoire de Neurologie Experimentale, Campus Hopital Erasme C2.124, 808 Route de Lennik, 1070 Bruxelles, Belgium.. Keywords:COMT gene, pharmacogenetics, antidepressant, treatment response, snp, Catechol O Methyl Transferase, Major Depressive disorder , COMT, MDD, rs4680, Antidepressant treatment, Dopamine. Abstract:Psychiatry is a specialty where the application of pharmacogenomics approaches is made to the study of interindividual differences in response to antidepressants. It is highly applied for improving patient treatment. Major depressive disorder (MDD) is a common and complex disorder resulting from genetic and environmental interactions. Less than 40% of patients with MDD achieve remission, and even after several treatment trials, one in three patients do not ...
This is a double-blind, placebo-controlled, randomized, multicenter proof-of-principle trial of adjunctive minocycline for patients with unipolar major depressive disorder (MDD). The study tests the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment with es-/citalopram, venlafaxine or mirtazapine monotherapy (AD-ST), for patients with unipolar major depressive disorder (MDD). The respective AD, for which non-response has been documented, must be on a stable regimen for at least 14 days prior to inclusion. AD-ST will then be continued throughout the trial. Trial medication is adjunct oral minocycline 200 mg/day or placebo. Response to treatment will be measured via the Montgomery-Asberg Depression Rating Scale (MADRS). The total study duration for each patient will be 6 weeks ...
OBJECTIVE: To examine the associations between diabetes, disability, and the likelihood of comorbid major depressive disorder (MDD) and generalized anxiety disorder (GAD).METHODS: Data were obtained from the 2012 Canadian Community Health Survey - Mental Health (N=17 623). Diabetes assessment consisted of a self-reported diagnosis of diabetes made by a health care professional. Disability was assessed via self-report. 12-Month and lifetime MDD and GAD were assessed with the Composite International Diagnostic Interview 3.0.RESULTS: In multinomial logistic regression models adjusted for sociodemographic and health-related factors, having diabetes was associated with a greater likelihood of 12-month comorbid MDD and GAD (OR=1.99, 95% CI [1.22, 3.25], p=.006), compared with those with neither MDD nor GAD. No significant associations were found for MDD without GAD or GAD without MDD. This pattern of effects held when lifetime diagnoses of MDD and GAD were considered. For individuals with diabetes ...
Major depressive disorder is the second leading cause of years lost to disability worldwide. Anyu Peibo Capsule has been shown to be effective and safe in phase II trials. This clinical study is a multi-center, randomized, double-blinded, placebo-controlled, parallel-group, phase III trial of Anyu Peibo Capsule in China. The aim is to test whether the administration of Anyu Peibo Capsule compared to placebo improves clinical outcomes in adults (aged 18 to 65 years) with MDD. Patients will receive an 8-week treatment of Anyu Peibo Capsule 1.6 g per day or placebo. The primary outcome will be the change from baseline in the total score for the Montgomery-Asberg Depression Rating Scale at the end of the 8-week treatment. The trial aims to provide pivotal evidence for the efficacy and safety of Anyu Peibo Capsule in patients with major depressive disorder. ClinicalTrials.gov NCT04210973 . Registered
Objective: Differences in dosing may influence results of pharmaceutical industry-sponsored medication trials. This study aims to determine the relationship between sponsorship and antidepressant dosing and efficacy in randomized controlled trials for major depressive disorder.. Data Sources: Trials were identified through English-language searches of MEDLINE and PsycINFO (January 1996-June 2010) using specific drug names and classes and depressive disorder or major depression and double blind or double-blind method. Other limitations included human subjects and treatment study designs using the clinical queries option. Other sources were also searched following a strict set of inclusion and exclusion criteria.. Study Selection: Randomized controlled trials were included if they examined antidepressant treatment for major depressive disorder, reported mean final medication dosages, acknowledged an association with industry, and included study arms of medications produced by the associated ...
121 outpatients ≥ 65 years of age (mean age 75 y, 77% women) with unipolar major depression (Diagnostic and Statistical Manual of Mental Disorders, 4th edition [DSM-IV], 296.2x or 296.3x and Montgomery Åsberg Depression Rating Scale [MADRS] score ≥ 22) who responded to acute and continuation treatment with citalopram (20 to 40 mg) for 8 and 16 weeks, respectively. Response to both phases of treatment was defined by a MADRS score ≤ 11. Exclusion criteria included an index episode that lasted , 12 months; a history of schizophrenia, mania, hypomania, epilepsy, or drug or alcohol misuse; and a score of ≥ 5 on MADRS item 10 (suicidality). Follow-up was 100 ...
Major depressive disorder (MDD) is common and disabling, but its neuropathophysiology remains unclear. Most studies of functional brain networks in MDD have had limited statistical power and data analysis approaches have varied widely. The REST-meta-MDD Project of resting-state fMRI (R-fMRI) address …
The word depression is often used by people to describe feelings of sadness or unhappiness, which all people experience at sometime in their lives. These meanings of depression can be confused with the word depression used to denote a serious mental disorder.. Clinical depression is not just feeling sad, it is a medical condition that affects the way mood is controlled by the brain. This leads to a variety of signs and symptoms that result in many problems in a persons life. This guide provides an overview of adolescent major depressive disorder, providing the reader with an understanding of the brain and mood control, what happens in depression and information about a wide variety of areas including: symptoms, treatment, why depression happens, myths and facts, resources and a glossary of terms.. ...
The article below may contain offensive and/or incorrect content.. Objective: Depression in patients with cancer has been associated with increased annual health care use and costs relative to nondepressed patients. Little is known of the potential cost savings associated with receipt of mental health treatment. This study evaluated the association between number of mental health visits and annual health care costs in patients with cancer and comorbid major depression. Method: Using a retrospective cohort study design, this study included 182 individuals with an ICD-9 chart diagnosis of cancer in 2014 and with comorbid major depressive disorder. The outcome of interest was annual health care charges 1 year from cancer diagnosis. Number of mental health visits was extracted from patients electronic medical records for the year following cancer diagnosis. A generalized linear model with a log link function and gamma distribution was used to evaluate the association between number of mental health ...
TY - JOUR. T1 - Comorbidity and its relevance on general hospital based mortality in major depressive disorder. T2 - a naturalistic 12-year follow-up in general hospital admissions. AU - Schoepf, Dieter. AU - Uppal, Hardeep. AU - Potluri, Rahul. AU - Chandran, Suresh. AU - Heun, Reinhard. PY - 2014/5. Y1 - 2014/5. N2 - Major depressive disorder (MDD) is associated with physical comorbidity, but the risk factors of general hospital-based mortality are unclear. Consequently, we investigated whether the burden of comorbidity and its relevance on in-hospital death differs between patients with and without MDD in a 12-year follow-up in general hospital admissions. During 1 January 2000 and 30 June 2012, 9604 MDD patients were admitted to three General Manchester Hospitals. All comorbidities with a prevalence ≥1% were compared with those of 96,040 age-gender matched hospital controls. Risk factors of in-hospital death were identified using multivariate logistic regression analyses. Crude ...
TY - JOUR. T1 - Regional brain volume reductions in major depressive disorder and bipolar disorder. T2 - An analysis by voxel-based morphometry. AU - Niida, Richi. AU - Yamagata, Bun. AU - Matsuda, Hiroshi. AU - Niida, Akira. AU - Uechi, Akihiko. AU - Kito, Shinsuke. AU - Mimura, Masaru. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Objectives: The present study investigated the usefulness of evaluating the existence of volume reduction in brain regions using voxel-based morphometry (VBM) to dissociate major depressive disorder (MDD) from bipolar disorder (BD). Methods/Design: This study enrolled 92 individuals with MDD, 32 individuals with BD, and 43 healthy controls (HCs). We focused on gray matter volume (GMV) of the subgenual anterior cingulate cortex (sgACC), subcallosal area (SCA), and hippocampus. The degree of volume reduction in these brain regions was calculated as the z score, and the differences of z scores in these regions were investigated among the MDD, BD, and HC groups. We then performed a ...
This is to our knowledge the first study investigating the impact of brain white-matter hyperintensities on antidepressant treatment outcome in a non-geriatric study sample. There are several important findings in this study. First, although we found no correlation between global white-matter hyperintensity measures and clinical outcome, subcortical hyperintensities in the left hemisphere were associated with poor outcome of antidepressant treatment. Previous studies in geriatric populations have described an association between subcortical and basal ganglia white-matter hyperintensity (and not periventricular hyperintensity) and poor treatment outcome in major depressive disorder (Hickie et al, 1997; OBrien et al, 1998; Simpson et al, 1998; Steffens et al, 2002). However, to our knowledge there is no other report indicating a differential impact of left-hemisphere subcortical white-matter hyperintensity on treatment outcome in major depressive disorder. Further studies will be needed to ...
Increasing amounts of data suggest that affective disorders might be related to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, one of the stress-response systems. Arginine vasopressin (AVP) influences several symptoms, relevant to affective disorders, notable memory processes, pain sensitivity, synchronization of biological rhythms and the timing and quality of REM sleep. We examined whether genetic variations in the AVP receptor 1b gene (AVPR1b) could be associated with increased susceptibility to affective disorders using a gene-based association analysis of single-nucleotide polymorphisms (SNPs). Five SNPs were identified in AVPR1b and genotyped in two well-diagnosed samples of patients with recurrent major depression and matched controls. In the Swedish sample, we observed significant allele (P=0.02) and genotype (P=0.01) association with SNP AVPR1b-s3, and in the Belgian sample, a borderline significant association with SNP AVPR1b-s5 (P=0.04). In both patient-control ...
Definition: a pervasive and persistent low mood, accompanied by low self-esteem, and a loss of interest or pleasure in normally enjoyable activities for more than two weeks. Major Depressive Disorder (MDD) is a disabling condition that adversely affects a persons family, work or school life, sleeping and eating habits, and general health. Long-term substance abuse may worsen the symptoms of major depression.. Symptoms: Five or more of the following symptoms need to be present in order to diagnose Major Depressive Disorder: depressed mood most of the day, nearly every day as indicated by a subjective report or observation by others; diminished interest or pleasure in all or almost all activities most of the day; significant weight loss (when not dieting) or weight gain (5% in a month) or increase/decrease in appetite; inability to sleep or sleep too much; restlessness or purposeless activity or physical movement slows down; fatigue or loss of energy; feelings of worthlessness or ...
Mental disorders are a major cause of long-term disability and are a direct cause of mortality, with approximately 800.000 individuals dying from suicide every year worldwide ? a high proportion of them related to major depressive disorder (MDD)1. Healthy relatives of patients with major depressive disorder (MDD) are at risk to develop the disease. This higher vulnerability is associated with structural2-4 and functional brain changes5. However, we found using high angular resolution diffusion imaging (HARDI) with 61 diffusion directions that neuron tracts between frontal cortices and limbic as well as temporal and parietal brain regions are characterized by better diffusion coefficients in unaffected relatives (UHR), who managed to stay healthy, compared to healthy volunteers without any family history for a psychiatric disease (HC). Moreover, those UHR with stronger fibre connections better managed incidences of adversity in early life without later developing depression, while in HC axonal ...
The aetiology of suicidal behaviour is complex, and knowledge about its neurobiological mechanisms is limited. Neuroimaging methods provide a noninvasive approach to explore the neural correlates of suicide vulnerability in vivo. The ENIGMA-MDD Working Group is an international collaboration evaluating neuroimaging and clinical data from thousands of individuals collected by research groups from around the world. Here we present analyses in a subset sample (n=3097) for whom suicidality data were available. Prevalence of suicidal symptoms among major depressive disorder (MDD) cases ranged between 29 and 69% across cohorts. We compared mean subcortical grey matter volumes, lateral ventricle volumes and total intracranial volume (ICV) in MDD patients with suicidal symptoms (N=451) vs healthy controls (N=1996) or MDD patients with no suicidal symptoms (N=650). MDD patients reporting suicidal plans or attempts showed a smaller ICV (P=4.12 × 10−3) or a 2.87% smaller volume compared with controls (Cohens d
Major Depressive Disorder News. Find breaking news, commentary, and archival information about Major Depressive Disorder From The tribunedigital-chicagotribune
Caroline L. Vandeleur, Sylfa Fassassi, Enrique Castelao, Jennifer Glaus, Marie-Pierre F. Strippoli, Aurélie M. Lasserre, Dominique Rudaz, Sirak Gebreab, Giorgio Pistis, Jean-Michel Aubry, Jules Angst, Martin Preisig, Prevalence and correlates of DSM-5 major depressive and related disorders in the community, Psychiatry Research, 2017, 250, ...
Major depressive disorder (MDD) is a debilitating mental disease with a pronounced impact on the quality of life of many people; however, it is still difficult to diagnose MDD accurately. In this study, a nontargeted metabolomics approach based on ultra-high-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) was used to find the differential metabolites in plasma samples from patients with MDD and healthy controls. Furthermore, a validation analysis focusing on the differential metabolites was performed in another batch of samples using a targeted approach based on the dynamic multiple reactions monitoring method. Levels of acyl carnitines, ether lipids, and tryptophan pronouncedly decreased, whereas LPCs, LPEs, and PEs markedly increased in MDD subjects as compared with the healthy controls. Disturbed pathways, mainly located in acyl carnitine metabolism, lipid metabolism, and tryptophan metabolism, were clearly brought to light in MDD ...
In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.
Abstract Despite the heterogeneous symptom presentation and complex etiology of major depressive disorder (MDD), functional neuroimaging studies have shown with remarkable consistency that dysfunction in mesocorticolimbic brain systems are central to the disorder. Relatively less research has focused on the identification of biological markers of response to antidepressant treatment that would serve to improve the personalized delivery of empirically supported antidepressant interventions. In the present study, we investigated whether resting-state functional brain connectivity (rs-fcMRI) predicted response to Behavioral Activation Treatment for Depression, an empirically validated psychotherapy modality designed to increase engagement with rewarding stimuli and reduce avoidance behaviors. Twenty-three unmedicated outpatients with MDD and 20 matched nondepressed controls completed rs-fcMRI scans after which the MDD group received an average of 12 sessions of psychotherapy. The mean change in ...
One barrier to interpreting past studies of cognition and Major Depressive Disorder (MDD) has been the failure in many studies to adequately dissociate the effects of MDD from the potential cognitive side effects of Selective Serotonin Reuptake Inhibitors (SSRI) use. To better understand how remediation of depressive symptoms affects cognitive function in MDD, we evaluated three groups of subjects: medication-naïve patients with MDD, medicated patients with MDD receiving the SSRI paroxetine and healthy control subjects. All were administered a category-learning task that allows for dissociation between learning from positive feedback (reward) versus learning from negative feedback (punishment). Healthy subjects learned significantly better from positive feedback than medication-naïve and medicated MDD groups, whose learning accuracy did not differ significantly. In contrast, medicated patients with MDD learned significantly less from negative feedback than medication-naïve patients with MDD and
Objective To investigate the risk factors that contribute to smoking in female patients with major depressive disorder (MDD) and the clinical features in depressed smokers. Methods We examined the smoking status and clinical features in 6120 Han Chinese women with MDD (DSM-IV) between 30 and 60 years of age across China. Logistic regression was used to determine the association between clinical features of MDD and smoking status and between risk factors for MDD and smoking status. Results Among the recurrent MDD patients there were 216(3.6%) current smokers, 117 (2.0%) former smokers and 333(5.6%) lifetime smokers. Lifetime smokers had a slightly more severe illness, characterized by more episodes, longer duration, more comorbid illness (panic and phobias), with more DSM-IV A criteria and reported more symptoms of fatigue and suicidal ideation or attempts than never smokers. Some known risk factors for MDD were also differentially represented among smokers compared to non-smokers. Smokers reported
TY - JOUR. T1 - Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis. AU - Yoshikawa, Eisho. AU - Matsuoka, Yutaka. AU - Yamasue, Hidenori. AU - Inagaki, Masatoshi. AU - Nakano, Tomohito. AU - Akechi, Tatsuo. AU - Kobayakawa, Makoto. AU - Fujimori, Maiko. AU - Nakaya, Naoki. AU - Akizuki, Nobuya. AU - Imoto, Shigeru. AU - Murakami, Koji. AU - Kasai, Kiyoto. AU - Uchitomi, Yosuke. PY - 2006/4/15. Y1 - 2006/4/15. N2 - Background: Major and minor depressive episodes in cancer patients are frequent and are frequently seen as the first depressive episode in a patients life. However, the neurological basis of these depressive episodes remains largely unknown. Methods: Subjects were 51 breast cancer survivors (BCS) who had no history of any depressive episode before the cancer diagnosis (11 BCS with a history of a first minor depressive episode after cancer diagnosis, 11 BCS with a history of a first major depressive episode after cancer diagnosis, ...
Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, a
Background: Major depressive disorder and generalized anxiety disorder are among the most commonly diagnosed mental illnesses in Canada; both are associated with a high societal and economic burden. Treatment for major depressive disorder and generalized anxiety disorder consists of pharmacological and psychological interventions. Three commonly used psychological interventions are cognitive behavioural therapy (CBT), interpersonal therapy, and supportive therapy. The objectives of this report were to assess the effectiveness and safety of these types of therapy for the treatment of adults with major depressive disorder and/or generalized anxiety disorder, to assess the cost-effectiveness of structured psychotherapy (CBT or interpersonal therapy), to calculate the budget impact of publicly funding structured psychotherapy, and to gain a greater understanding of the experiences of people with major depressive disorder and/or generalized anxiety disorder ...
During and around the time of the episode, adolescent major depression is associated with psychological suffering, impairment in social roles, and increased risk for suicide. In this paper, Lewinsohn and colleagues show that adolescents with depression have poorer psychosocial functioning than never depressed adolescents-as reviewed in their article, this exactly parallels similar findings in other studies. The impairment shown in this work was broad, spanning occupational performance, interpersonal functioning, quality of life, and physical well being. The important contribution of this particular paper is in the examination of the specificity of this relationship and of alternative causal models.. In their examination, most of the psychosocial impairment appears to be associated with psychopathology in general and not with depression per se. While this perhaps should come as no surprise, the demonstration provided in this paper is elegant and convincing.. The deeper question is whether or not ...
DSM-5 Fine-Tunes Diagnostic Criteria for Psychosis, to diagnostic criteria in DSM-5 between now and its publication date in May. Keywords: Psychotic.. Criteria for Severity/Psychotic/Remission Specifiers for current (or most recent) Major Depressive Episode. Note: These criteria are coded for in fifth digit of the DSM-IV diagnostic code. Can be applied to the most recent Major Depressive Episode in Major Depressive Disorder and to a Major Depressive Episode in Bipolar I.. They include depression with psychotic features, which occurs when a severe depressive illness is accompanied by some form of psychosis, such as a break with reality, The diagnostic criteria and key defining features of major depressive disorder in children and adolescents are the same as they are for adults. Research.. Hypomania is similar to mania; however, it is not serious enough to cause social or occupational impairment, hospitalization, or psychotic features (American. The criteria is presented for the mood episodes that ...
AIM: The aim of this study was to investigate heart rate variability (HRV) in a clinical sample of female adolescents with anxiety disorders (AD) and/or major depressive disorder (MDD) compared with healthy controls and to assess the effect of selective serotonin reuptake inhibitors (SSRI) on HRV.. METHODS: Heart rate variability was measured in adolescent female psychiatric patients with AD and/or MDD (n = 69), mean age 16.8 years (range: 14.5-18.4), from 13 out-patient clinics and in healthy controls (n = 65), mean age 16.5 years (range: 15.9-17.7). HRV was registered in the sitting position during 4 min with no interventions.. RESULTS: Logarithmically transformed high frequency HRV (HF), low frequency HRV (LF) and standard deviation of inter beat intervals (SDNN) were lower in the clinical sample compared with the controls (Cohens d for HF = 0.57, LF = 0.55, SDNN = 0.60). This was not explained by body mass index, blood pressure or physical activity. Medication with SSRI explained 15.5% of ...
Health, ... Major depressive disorder is a common and complex condition that impa... In findings published electronically in Molecular Psychiatry researc... The study population was made up of 284 depressed Mexican-Americans f... Our findings suggest that a simple blood test to look for these genes...,Inflammation,,depression,and,antidepressant,response:,Common,mechanisms,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
We investigated the influence of detached mindfulness (DM) in treating symptoms of depression and anxiety among elderly women. Thirty-four elderly females (mean age: 69.23 years) suffering from moderate major depressive disorders (MDD) and treated with a standard medication (citalopram) at therapeutic doses were randomly assigned either to an intervention condition (DM; group treatment, twice weekly) or to a control condition (with leisure activities, twice weekly). At baseline (BL), four weeks later at study completion (SC), and four weeks after that at follow-up (FU), participants completed ratings for symptoms of depression and anxiety; experts blind to patients group assignments rated patients symptoms of depression. Symptoms of depression (self and experts ratings) and anxiety declined significantly over time in the DM, but not in the control condition. Effects remained stable at FU. The pattern of results suggests that, compared to a control condition, a specific psychotherapeutic ...
This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disorder (MDD) [NCT02116361]. Primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS); …
A study presented today at the 160th Annual Meeting of the American Psychiatric Association showed that, in adults with major depressive disorder, adding ABILIFY(R)(aripiprazole) to antidepressant therapy resulted in significant improvement in the primary endpoint, the MADRS Total Score. A reduction in MADRS Total Score represents improvement in depressive symptoms.
Background: Major depressive disorder and generalized anxiety disorder are among the most commonly diagnosed mental illnesses in Canada; both are associated with a high societal and economic burden. Treatment for major depressive disorder and generalized anxiety disorder consists of pharmacological and psychological interventions. Three commonly used psychological interventions are cognitive behavioural therapy (CBT), interpersonal therapy, and supportive therapy. The objectives of this report were to assess the effectiveness and safety of these types of therapy for the treatment of adults with major depressive disorder and/or generalized anxiety disorder, to assess the cost-effectiveness of structured psychotherapy (CBT or interpersonal therapy), to calculate the budget impact of publicly funding structured psychotherapy, and to gain a greater understanding of the experiences of people with major depressive disorder and/or generalized anxiety disorder ...
Background Amino acid neurotransmitters and nitric oxide (NO) are involved in the pathogenesis of major depressive disorder (MDD). Here we want to establish whether changes in their plasma levels may...
BACKGROUND: There is increasing evidence for a link between cerebrovascular disease and depression in the elderly but the mechanisms are still unknown. This study examines the longitudinal relationship between depression and white matter lesions (WML) in a sample of elderly aged 65 years and older. METHODS: Three City (3C)-Dijon is a 4-year follow-up population-based prospective study of 1658 subjects. At baseline, lifetime major depressive episode diagnosis was established using the Mini International Neuropsychiatric Interview. At each study wave, severity of depressive symptoms was assessed using Center for Epidemiological Studies-Depression (CES-D), and antidepressants intake was recorded. At baseline, lifetime major depression (LMD) was defined as lifetime major depressive episode or antidepressant medication intake. At follow-up, subjects were classified incident depression if scoring high at CES-D or antidepressant users. At baseline, cerebral magnetic resonance imaging (MRI) was performed to
After a year of treatment with minimal improvement, I suggested Transcranial Magnetic Stimulation. The patient agreed and within three weeks she was back doing crossword puzzles and cooking. Within four weeks she was spending more time with her grandchildren - she looked forward to going to work, her concentration was much better, she reconnected with her friends, enjoyed going out to dinner with family, gained back weight she had lost and felt her life was meaningful again.. TMS is the latest non-pharmaceutical treatment modality for major depressive disorder that does not respond to other treatments. In a large clinical trial done by the National Institute of Mental Health involving more than 4,000 patients, it was found that only 30 percent of patients treated with antidepressants were totally free of any symptoms of depression.. TMS works by stimulating key neurons in the brain believed to be involved in the pathophysiology of depression. Unlike antidepressants that are swallowed and ...
A person is diagnosed with Major Depressive Disorder when they experience five or more of the following symptoms during the same two-week period for most of the day or nearly every day:
TY - JOUR. T1 - Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent major depressive disorder. AU - Na, Kyoung Sae. AU - Won, Eunsoo. AU - Kang, June. AU - Chang, Hun Soo. AU - Yoon, Ho-Kyoung. AU - Tae, Woo Suk. AU - Kim, Yong Ku. AU - Lee, Min-Soo. AU - Joe, Sook Haeng. AU - Kim, Hyun. AU - Ham, Byung-Joo. PY - 2016/2/15. Y1 - 2016/2/15. N2 - Recent studies have reported that methylation of the brain-derived neurotrophic factor (BDNF) gene promoter is associated with major depressive disorder (MDD). This study aimed to investigate the association between cortical thickness and methylation of BDNF promoters as well as serum BDNF levels in MDD. The participants consisted of 65 patients with recurrent MDD and 65 age-and gender-matched healthy controls. Methylation of BDNF promoters and cortical thickness were compared between the groups. The right medial orbitofrontal, right lingual, right lateral occipital, left lateral orbitofrontal, left pars ...
There is substantial evidence that cognitive therapy is an effective intervention for the treatment of major depressive disorder. Although dynamic psychotherapies have been widely studied and are commonly practiced worldwide, there are few randomized comparisons of cognitive therapy and dynamic therapy for major depressive disorder. We are completing data collection on a randomized non-inferiority trial comparing the effectiveness of cognitive therapy and short-term dynamic psychotherapy in the treatment of major depressive disorder in the community mental health setting. Therapists employed in the community setting have been recruited for training in either short-term dynamic psychotherapy or cognitive therapy. Patients seeking services at the community site who meet criteria for major depressive disorder based on a blind independent diagnostic interview are randomized to 16 sessions of treatment. All patients are assessed at baseline and months 1, 2, 4, and 5 utilizing a comprehensive battery. This
Abstract: Research has shown that nocturia and major depressive disorder are often correlated. The clinician should take a complete history along with performing a physical examination when patients present with symptoms that may be associated with nocturia. Patients rarely seek medical attention solely for treatment of nocturia, so direct questions along with use of the Frequency Volume Chart (FVC) should be used to assess whether underlying disorders or conditions are present. Clinicians should also be alert to the possible presence of nocturia in patients who suffer from major depressive disorder since nocturia rates for this population is significantly higher. Behavioural modifications alone may be insufficient to improve nocturia where clinically depressive symptoms are also present. Pharmacological treatments may provide improvement when nocturia and major depressive disorder are both present ...
TY - JOUR. T1 - Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?. AU - Kamara, Taafoi S.. AU - Whyte, Ellen M.. AU - Mulsant, Benoit H.. AU - Peasley-Miklus, Catherine. AU - Rothschild, Anthony J.. AU - Flint, Alastair J.. AU - Heo, Moonseong. AU - Papademetriou, Eros. AU - Mathis, Erin R.. AU - Meyers, Barnett S.. PY - 2009/1/1. Y1 - 2009/1/1. N2 - Background: Among patients with major depression with psychotic features, little is known about the extent to which those with and without somatic delusions differ. Methods: The first 183 participants in the STOP-PD study were divided into two groups based on the presence or absence of somatic delusions and were compared on multiple demographic and clinical characteristics. Results: In the multivariate analysis, those with somatic delusions reported more somatic symptoms, rated their health as worse, and were less likely to have persecutory delusions. ...
Looking for online definition of major depressive episode in the Medical Dictionary? major depressive episode explanation free. What is major depressive episode? Meaning of major depressive episode medical term. What does major depressive episode mean?
Background: In a previous prospective study of 300 consecutive new attenders at neurology outpatient clinics, depressive disorders were diagnosed in 119 patients (40%) and major depressive disorder in 77 (26%).. Objective: To describe the eight month outcome of depression in this cohort.. Methods: Patients were reinterviewed eight months after their baseline assessment. Mental state was examined using the primary care evaluation of mental disorders (PRIME-MD) interview and the hospital anxiety and depression (HAD) self rating scale. Health status was measured using the medical outcome study 36 item short form scale (SF-36).. Results: Of the original cohort of 300, 226 (75%) participated in the follow up. Among them, 88 had a depressive disorder at baseline and 69 (78%) of those were still depressed at follow up; 54 had major depression at baseline and 46 (85%) of those still had a major depressive disorder at follow up. Among the 138 patients who had no depression at baseline, 20 new major ...
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies Michael E Thase,1 Emmanuelle Weiller,2 Peter Zhang,3 Catherine Weiss,4 Roger S McIntyre5 1Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA; 2Medical Affairs, H. Lundbeck A/S, Valby, Copenhagen, Denmark; 3Biostatistics Department, Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ, USA; 4Global Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ, USA; 5Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada Objective: Episodes of major depressive disorder (MDD) characterized by high levels of anxiety symptoms are less likely to respond to some forms of antidepressant treatment (ADT). This report examines the effects of adjunctive
TY - JOUR. T1 - Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence. AU - Andersen, Allan M.. AU - Pietrzak, Robert H.. AU - Kranzler, Henry R.. AU - Ma, Li. AU - Zhou, Hang. AU - Liu, Xiaoming. AU - Kramer, John. AU - Kuperman, Samuel. AU - Edenberg, Howard. AU - Nurnberger, John. AU - Rice, John P.. AU - Tischfield, Jay A.. AU - Goate, Alison. AU - Foroud, Tatiana. AU - Meyers, Jacquelyn L.. AU - Porjesz, Bernice. AU - Dick, Danielle M.. AU - Hesselbrock, Victor. AU - Boerwinkle, Eric. AU - Southwick, Steven M.. AU - Krystal, John H.. AU - Weissman, Myrna M.. AU - Levinson, Douglas F.. AU - Potash, James B.. AU - Gelernter, Joel. AU - Han, Shizhong. PY - 2017/11/1. Y1 - 2017/11/1. N2 - Importance: Major depressive disorder (MDD) and alcohol dependence (AD) are heritable disorders with significant public health burdens, and they are frequently comorbid. Common genetic factors that influence the co-occurrence of MDD and AD have been sought in family, twin, and adoption ...
The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the persons weight and site of bone measurement.. Osteoporosis is a common disorder and an underlying factor in fragility fractures. Especially in women, the menopause increases the risk of osteoporosis. Other risk factors include low levels of physical activity, smoking, low intake of calcium and vitamin D, as well as some medications and diseases. In the elderly, susceptibility to fracture and serious hip fractures can result in long-term hospitalization and decreased state of health.. Previous studies have shown that also depression is associated with lower bone density. This might be due to the effects of depression-induced long-term stress and increased secretion of inflammatory markers. Furthermore, selective serotonin reuptake inhibitors (SSRIs) used to treat depression have been shown to weaken bone health. However, the majority of studies has focused on ...
Background and Objectives. Several gene variants have been related to major depressive disorder (MDD) treatment outcomes; however, few studies have investigated a possible different effect on pharmacotherapy and brief psychotherapy response. Methods. A total of 137 MDD patients were randomized to either interpersonal counseling (IPC; n = 40) or anti-depressant pharmacological treatment (n = 97). Outcomes were remission, response, and symptom improvement at week 8. Five genetic variants were investigated (5HTR2A rs6314, BDNF rs6265, SLC6A4 rs8076005, CREB1 rs2253206, and TPH2 rs11179023) as possible modulators of outcomes. Results. The LC6A4 rs8076005 AA genotype and A allele were associated with response rate in the antidepressant group (p = 0.015 and 0.005, respectively) and in the whole sample (p = 0.03 and 0.02, respectively). In the IPC group a non-significant trend in the same direction was observed. The TPH2 rs11179023 A allele showed a marginal association with symptom improvement in the ...
Atypical depression is basically a subtype of clinical depression. It exhibits less severe and fewer number of symptoms than clinical depression. This type of depression differs from major depression. The patient may also experience moments of happiness sometimes.. The symptoms of atypical depression may last for months or even stay forever. The mood of the patients is governed by the outside events like success or failure, etc.. Causes of Atypical Depression. Chemical imbalance in the brain is responsible for causing Depression in the patients. The changes in the level of neurotransmitters such as dopamine, serotonin, and nor-epinephrine are supposed to cause depression.. Risk factors for Atypical Depression. ...
Leo Sher, M.D.. Ten years ago, our research paper, Depressed patients with co-occurring alcohol use disorders: a unique patient population was published in the Journal of Clinical Psychiatry (1). We compared depressed subjects with and without co-occurring alcohol use disorder with respect to demographic and clinical parameters.. 505 individuals were enrolled in the study. 318 subjects who had major depressive disorder without a history of any alcohol or substance abuse/dependence were compared to 187 individuals who had major depressive disorder and a history of alcohol abuse/dependence.. Individuals with major depressive disorder and a history of alcohol abuse/dependence were younger at their first psychiatric hospitalization, their first major depressive episode, and their first suicide attempt. They reported more previous major depressive episodes, suicide attempts, and recent life events; and had higher lifetime aggression, impulsivity, and hostility scores. Patients with major depressive ...
Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta has been established in 8- and 9-week placebo-controlled trials of outpatients who met DSM-IV diagnostic criteria for major depressive disorder.. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. The effectiveness of Cymbalta in hospitalized patients with major depressive disorder has not been studied. The effectiveness of Cymbalta in long-term use for major depressive disorder, that is, for more than ...
Peripartum onset is specified if the onset to symptoms occurs during pregnancy or 4 weeks following delivery. Postpartum mood (major depressive or manic) occurs in 1 in 500 to 1 in 1000 deliveries. The risk of postpartum with psychotic features is increased for women with a history of depression, bipolar disorder or a family history of bipolar (DSM-5). Additional specifies include anxious distress, mixed features, melancholic, atypical features, mood-incongruent psychotic features, mood-congruent psychotic features, catatonia, and seasonal pattern.. The incidence of Major Depressive disorder in 18 to 20 year olds is three times that of 60 year olds. Onset is more common in adolescence, but can appear at any age. Females are diagnosed with depression 1.5 to 3 times more than males (DSM-5). People with depression are at risk of suicide, especially if they have made attempts or threats in the past. According to DSM-5. high levels of negativity, a difficult childhood, and life stressors like divorce ...
There are several forms of depressive disorders. The most common are major depressive disorder and dysthymic disorder.. Major depressive disorder, also called major depression, is characterized by a combination of symptoms that interfere with a persons ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Major depression is disabling and prevents a person from functioning normally. An episode of major depression may occur only once in a persons lifetime, but more often, it recurs throughout a persons life.. Dysthymic disorder, also called dysthymia, is characterized by long-term (two years or longer) but less severe symptoms that may not disable a person but can prevent one from functioning normally or feeling well. People with dysthymia may also experience one or more episodes of major depression during their lifetimes.. Some forms of depressive disorder exhibit slightly different characteristics than those described above, or they may develop under unique ...
There are several forms of depressive disorders. The most common are major depressive disorder and dysthymic disorder.. Major depressive disorder, also called major depression, is characterized by a combination of symptoms that interfere with a persons ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Major depression is disabling and prevents a person from functioning normally. An episode of major depression may occur only once in a persons lifetime, but more often, it recurs throughout a persons life.. Dysthymic disorder, also called dysthymia, is characterized by long-term (two years or longer) but less severe symptoms that may not disable a person but can prevent one from functioning normally or feeling well. People with dysthymia may also experience one or more episodes of major depression during their lifetimes.. Some forms of depressive disorder exhibit slightly different characteristics than those described above, or they may develop under unique ...
On September 30, the U.S. Food and Drug Administration approved Brintellix (vortioxetine) to treat adults with major depressive disorder (MDD). Six clinical studies in which adults with MDD were randomly assigned to receive Brintellix or placebo demonstrated that Brintellix is effective in treating depression, according to the FDA press release. An additional study showed Brintellix decreased the likelihood of participants becoming depressed again after treatment of their MDD episode. Brintellix is co-marketed by Takeda Pharmaceuticals and Lundbeck, both based in Deerfield, Ill. Studies were conducted in the United States and other countries, and included more than 4,700 patients aged 18 to 88 years. The clinical trial program included six positive 6-8 week short-term studies, one of which was a dedicated study in the elderly. Takeda and Lundbeck report that the primary efficacy measure was the mean change from baseline to endpoint in the Hamilton Depression Scale (HAMD-24) total score in two ...
This trial evaluated the efficacy of sertraline in Japanese patients with major depressive disorder. The primary outcome was the Hamilton Rating Scale for
Background: Major depressive disorder (MDD) has been associated with a high cardiovascular morbidity and mortality; however the pathophysiological mechanisms responsible for this association have not been elucidated. The aim of this study was to assess whether MDD was related with vascular endothelial dysfunction in patients with acute myocardial infarction (AMI).. Methods: A cross-sectional study including 156 patients (116 men, 40 women) with acute myocardial infarction (AMI) was performed. A blood sample was collected before hospital discharge for C-reactive protein (CRP), IL-1, TNF-α and plasma nitrites/nitrates determination. In addition a brachial flow mediated vasodilation (FMD), a measure of endothelial function, and a structured clinical interview for MDD diagnosis were performed.. Results: Mean age of included subjects was 64±11.5 years. Twenty subjects (13.3%) were diagnosed with MDD. Subjects with MDD presented a lower FMD (3.5±2.04 % vs 6.1±3.4 %, p=0,02) and higher CRP values ...
Carbamazepine major depressive disorder. Difference Between Lamotrigine and Carbamazepine As it is too early to pinpoint the specific disorders that Lamotrigine is most effective Major Depression;.
BACKGROUND: The genetics of depression has been explored in genome-wide association studies that focused on either major depressive disorder or depressive symptoms with mostly negative findings. A broad depression phenotype including both phenotypes has not been tested previously using a genome-wide association approach. We aimed to identify genetic polymorphisms significantly associated with a broad phenotype from depressive symptoms to major depressive disorder. METHODS: We analyzed two prior studies of 70,017 participants of European ancestry from general and clinical populations in the discovery stage. We performed a replication meta-analysis of 28,328 participants. Single nucleotide polymorphism (SNP)-based heritability and genetic correlations were calculated using linkage disequilibrium score regression. Discovery and replication analyses were performed using a p-value-based meta-analysis. Lifetime major depressive disorder and depressive symptom scores were used as the outcome measures. RESULTS:
Wayne State researchers have identified a novel method to differentiate children with major depressive disorder from normal and children with obsessive compulsive disorder (OCD).
TY - JOUR. T1 - Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder. AU - Sakurai, Masashi. AU - Yamamoto, Yasuko. AU - Kanayama, Noriyo. AU - Hasegawa, Masaya. AU - Mouri, Akihiro. AU - Takemura, Masao. AU - Matsunami, Hidetoshi. AU - Miyauchi, Tomoya. AU - Tokura, Tatsuya. AU - Kimura, Hiroyuki. AU - Ito, Mikiko. AU - Umemura, Eri. AU - Boku, Aiji Sato. AU - Nagashima, Wataru. AU - Tonoike, Takashi. AU - Kurita, Kenichi. AU - Ozaki, Norio. AU - Nabeshima, Toshitaka. AU - Saito, Kuniaki. N1 - Funding Information: This work was partly supported by JSPS KAKENHI grant numbers 15H03086, 18K19761 (KS), 17H07222, 19K07490 (YY) and 17H04252 (TN); AMED under grant No. JP19dk0307075 (NO); the Private University Research Branding Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), and by a research grant from the Smoking Research Foundation (KS). Publisher Copyright: © 2020, The ...
Serum alpha-1-acid glycoprotein (AGP) concentration and its microheterogeneity were measured in 46 patients with major depressive disorder and in 20 age- and sex-matched controls. The changes in major...
LONDON - The worldwide depressive disorder market is anticipated to witness positive growth in the years to come and to overcome declining revenues owing to patent expiry and introduction of better innovative therapies and drugs.. The highest prevalence of depression disorder and also bipolar depression and schizophrenia is registered in the US. Due to enhancing awareness along with expanding access to medical facilities, the depressive disorder market is anticipated to enjoy remarkable growth across the globe, especially in the APAC region.. Major factors propelling growth in the depressive disorder market includes increasing healthcare expenditures, rising smoking prevalence, increasing female population, surging number of prescription drugs and enhancing spending on medicines, among others. At the same time, some factors like tough regulations, patent expiry and severe side effects of drugs could restrain growth in the depressive disorder market.. The new research publication Global ...
Context The corticotropin-releasing factor (CRF, or corticotropin-releasing hormone) and arginine vasopressin systems have been implicated in the pathophysiology of anxiety and depressive disorders and response to antidepressant treatment.. Objective To study the association of genetic variants in 10 genes that regulate the CRF and arginine vasopressin systems with treatment response to citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample (N = 1768).. Design Pharmacogenetic association study derived from the STAR*D study, a multicenter, prospective, open, 12-week effectiveness trial.. Setting Outpatient primary care and psychiatric clinics.. Patients Individuals with nonpsychotic major depressive disorder for whom DNA was available who were subsequently treated with citalopram hydrobromide for 4 to 12 weeks.. Intervention Flexible doses of citalopram.. Main Outcome Measure Association of genetic polymorphisms in genes encoding the CRF system with response and ...
BACKGROUND: Depression is a common problem in all medically ill populations. Reported prevalence rates of major depression in patients with cancer are up to 50%. Cancer patients attending primary care and medical outpatient clinics with comorbid major depressive disorder frequently do not receive effective treatment. More effective ways of identifying and treating patients with both cancer and depression are therefore urgently required. AIM: The paper reports a study addressing the question of whether oncology nurses can be trained to take on a greater role in the management of major depression in their patients. METHOD: We developed and piloted an intervention that can be delivered by a specially trained oncology nurse. The intervention is multifaceted and based on a problem-solving model. It requires a widening of the role and expertise of specialist nurses. DISCUSSION: The challenges this role presents to the nurses are discussed. We suggest that they must have a varied work programme that is not
The US-based Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project [17] enrolled a total of 4,041 treatment-seeking adults. All patients included in the study had a diagnosis of non-psychotic major depressive disorder (as confirmed by DSM-IV criteria), scoring greater than 14 on the HAM-D (that is, suffered from moderate to severe depression). Among the sample, there were high rates of chronic or recurrent depression. STAR*D had a multistep design; all patients received citalopram (an SSRI) in the first treatment level, then those without sufficient symptomatic benefit moved onto further treatment levels where they received either alternative or augmented treatment options.. STAR*D is the largest and longest study to ever be conducted evaluating antidepressant treatments. It was found that with first-level treatment with citalopram, approximately 30% of patients achieved remission. While the study was not expressly designed for pharmacogenetic purposes, DNA was collected from ...
Current antidepressants used to treat pediatric patients have the disadvantage of limited efficacy and potentially serious side effects. The purpose of this study was to assess the efficacy of vitamin C as an adjuvant agent in the treatment of pediatric major depressive disorder in a six-month, double-blind, placebo-controlled pilot trial. The study group (n=12) was given fluoxetine (10-20 mg/day) plus vitamin C (1000 mg/day) and control group (n=12) administered fluoxetine (10-20 mg/day) plus placebo. The data were analyzed by ANOVA and t-test for independent samples. Both groups demonstrated significantly improved scores on the Childrens Depression Rating Scale (CDRS), the Childrens Depression Inventory (CDI), and the Clinical Global Impression (CGI). ANOVA was significantly different on all clinical measurements (group effect, time effect, and interaction), with the exception of group effect and interaction for CGI. Patients treated for six months with fluoxetine and vitamin C showed a significant
Major Depression - MedHelps Major Depression Center for Information, Symptoms, Resources, Treatments and Tools for Major Depression. Find Major Depression information, treatments for Major Depression and Major Depression symptoms.
Depression is one of the most common mental health issues that plagues modern Americans. Often found hand-in-hand with anxiety disorders, depression is notorious for erecting severe roadblocks in peoples lives. Fortunately, there are several effective clinical treatments as well as a number of activities and behaviors that can be adopted to curb the negative effects of depression, also known as major depressive disorder. Check out these helpful behaviors and activities that prove effective in managing depression when added to depression counseling in Gulf Shores, AL. Exercise. Without going into too much clinical detail, depression is caused by an imbalance of chemicals in the brain known formally as neurotransmitters. The neurotransmitters affected by major depressive disorder are dopamine, serotonin and norepinephrine. Exercise is proven to stimulate the release of all three of these neurotransmitters, which has a positive effect on people who suffer from depression. Maintain a Balanced, ...
Use of Fluoxetine in Children - The efficacy of fluoxetine for the treatment of Major Depressive Disorder was demonstrated in two 8- to 9-week placebo-controlled clinical trials with 315 pediatric outpatients ages 8 to ≤18 [see Clinical Studies (14.1)].. The efficacy of fluoxetine for the treatment of OCD was demonstrated in one 13-week placebo-controlled clinical trial with 103 pediatric outpatients ages 7 to ,18 [see Clinical Studies (14.2)].. The safety and effectiveness in pediatric patients ,8 years of age in Major Depressive Disorder and ,7 years of age in OCD have not been established.. Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (ages 6 to ≤18) with Major Depressive Disorder or OCD [see Clinical Pharmacology (12.3)].. The acute adverse reaction profiles observed in the 3 studies (N=418 randomized; 228 fluoxetine-treated, 190 placebo-treated) were generally similar to that observed in adult studies with fluoxetine. The longer-term adverse reaction profile ...
Background: Depression diagnosis requires five or more symptoms (Diagnostic and Statistical Manual of Mental Disorders-DSM-5). One of them must be either Depressed mood or Anhedonia, named main criteria. Although the secondary symptoms can be divided into somatic and non-somatic clusters, the DSM-5 identify depression in all or none fashion. In contrast, depression severity is a continuous variable. Therefore, it is commonly assessed with scales such as the Hamilton Depression Rating Scale (HAMD). Previously, we reported that patients with moderate depression (MD) exhibit greater impairments in cardiac-autonomic modulation than severely depressed (SD) patients. However, clinicians usually do not use scales.Objective: To verify whether the DSM-5 symptoms would be able to discriminate SD from MD and MD from non-depressed (ND) subjects.Material and Methods: Depression was diagnosed based on the Structured Clinical Interview for DSM-5® Disorders. The HAMD evaluated depression severity. In depressed
Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist ...